Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691794 · ClinicalTrials.gov registry record · Phase 4
Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
NCT01691794 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 108 participants.
The verdict
NCT01691794, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to collect safety clinical data in HIV-infected pediatric patients aged 6 and older to younger than18 years and weighing 15 kg or more, who are receiving atazanavir capsule boosted with ritonavir and an optimized nucleoside reverse transcriptase inhibitor backbone therapy as part of their antiretroviral regimen.
Interventions
- DRUG Ritonavir
- DRUG Atazanavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2012-11-30 |
| Est. Completion | 2017-02-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01691794
The ClinicalTrials.gov registry entry for NCT01691794 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ritonavir is the first listed.
NCT01691794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01691794 about?
NCT01691794 is a clinical study titled "Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients". The purpose of this study is to collect safety clinical data in HIV-infected pediatric patients aged 6 and older to younger than18 years and weighing 15 kg or more, who are receiving atazanavir capsule boosted with ritonavir and an optimized nucleoside reverse transcriptase inhibitor backbone therap...
What is the current status of trial NCT01691794?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2012-11-30. Estimated completion is 2017-02-20.
What interventions are being tested in trial NCT01691794?
The interventions under investigation include: Ritonavir (DRUG), Atazanavir (DRUG).
Who is sponsoring clinical trial NCT01691794?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.